Global Humanized Mouse and Rat Model Market Size, share and Forecast

The Research Report on "Humanized Mouse and Rat Model Market by Type (Genetic, Cell-Based (CD34, PBMC, BLT)), Application (Neuroscience, Hematopoesis, Oncology, Immunology & Infectious Diseases) & End User (Pharmaceutical & Biotechnology Companies, CRO)) – Global Forecast" published by MarketsandMarkets™.

The humanized mouse models market to grow from USD 73.9 million, to USD 128.9 million, at a CAGR of 9.9% during the forecast period.

The humanized rat models market is expected to reach USD 8.9 million, at a CAGR of 8.4% during the forecast period.

The Growth in Humanized Mouse and Rat Model Market can primarily be attributed to factors such as the growing demand of personalized medicine, continuous support in the form of investments and grants from the government and private sectors, increasing number of R&D activities in pharmaceutical and biotechnology companies, and the increasing number of research activities involving humanized models. Increasing production of monoclonal antibodies and rising demand for humanized rat models are expected to provide a wide range of growth opportunities for players in the market.

Opportunity: Increased production of monoclonal antibodies;

With personalized medicine gaining in importance, monoclonal antibodies (mAbs) showcase an enormous potential to treat a wide range of diseases. This is a positive indicator for market growth as mouse models are extensively used in the production of mAbs. Researchers have replaced few parts of mouse antibodies with human components; the final antibodies with a mixture of human and mouse components are known as chimeric antibodies. Some monoclonal antibodies are now entirely human as a larger portion of the human component is engrafted in the mouse antibody.

Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=131763955

The oncology segment commanded the largest share of the humanized rat models market

By application, Categorized into oncology, immunology and infectious diseases, neuroscience, hematopoiesis, toxicology, and other applications. Of all these application segments, oncology accounted for the largest share of the humanized mouse models market in 2017. The increasing research activities and growing funding from various governments to carry out research studies on cancer are the major factors driving the growth of this segment.

Cell-based humanized mouse models to grow at the highest CAGR during the forecast period

By type, Categorized into genetic and cell-based humanized mouse models. The cell-based humanized mouse models segment is expected to grow at the highest CAGR during the study period (2017–2022). The high growth of this segment can be attributed to the growing applications of cell-based humanized mouse models.

The cell-based humanized mouse models segment is further categorized into CD34, PBMC, and BLT humanized mouse models. In 2017, the CD34 models segment commanded the largest share of the cell-based humanized mouse models market and is expected to grow at the highest CAGR during the forecast period. CD34 mouse models are used as in vivo platforms for analyzing the safety and effectiveness of potential new drugs that can modulate the immune system. They are used for long-term studies in the fields of immuno-oncology, infectious disease, and graft versus host disease. Thus, the growing application areas of CD34 models are expected to trigger the demand for these models in the coming years.

Geographically; North America dominated the global humanized mouse models market. Growth in this regional segment can be attributed to the increasing monoclonal antibody production, preclinical activities by CROs and pharmaceutical R&D, continued and responsible use of animals ensured by animal care organizations, growing biomedical research in the US along with government support for the development of protein drugs, and growing stem cell research in Canada.

The major market players in the humanized mouse models market include The Jackson Laboratory (US), Taconic Biosciences, Inc. (US), Horizon Discovery Group plc (UK), genOway, S.A. (France), Charles River Laboratories (US), Harbour Antibodies BV (China), Hera BioLabs (US), Vitalstar Biotechnology Co., Ltd. (China), inGenious Targeting Laboratory (US), AXENIS S.A.S (France), Crown Bioscience, Inc. (US), Transgenic, Inc. (Japan), and Champions Oncology, Inc. (US). The major players in the humanized rat models market include Horizon Discovery Group plc (UK), Hera BioLabs (US), and Yecuris Corporation (US).

Taconic is the second most leading players in the global humanized mouse and rat model market. The company is a provider of cell based and genetically modified mice models and supporting services such as custom model generation, imaging studies, and surgical services. The firm also has other distribution networks in India, Japan, and Singapore. A broad distribution network and a wide range of humanized mouse strains position the firm as one of the major players in the global cell based and genetic humanized mouse model market.

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 com